Cis-enone Resorcylic Acid Lactones (RALs) as Irreversible Protein Kinase Inhibitors

Current Pharmaceutical Design

Volumn 18, Issue 9, 2012, Pages 1186-1198

  Wei, Linyi ^a   Wu, Jiuhong ^b   Li, Guanqun ^c   Shi, Ning ^b  

^a SAIC FREDERICK INC   (United States)

^b 306 HOSPITAL OF PLA   (China)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Irreversible protein kinase; Mapk kinases; Resorcylic acid lactones (RALs)

Indexed keywords

5Z 7 OXOZEAENOL; ADENOSINE TRIPHOSPHATE; APOPTOSIS SIGNAL REGULATING KINASE 1; CYSTEINE; ER 803064; I KAPPA B; L 783,277; LACTONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; RADICICOL A; RESORCYLIC ACID LACTONE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

BIOCHEMISTRY; CHEMICAL MODIFICATION; COVALENT BOND; DEREGULATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; MICHAEL ADDITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; LACTONES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RESORCINOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863281519     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436395     Document Type: Review

References (54)

1. Johnson GL, Lapadat R. Mitogen-activated protein kinase path-ways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-2.
2. Cohen P. Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-15.
3. Johnson LN, Lowe ED, Noble ME, Owen DJ. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett 1998; 430: 1-11.
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
5. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39
6. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-64.
7. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
8. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009; 5: 281-9.
9. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754: 3-13.
10. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell 2004; 116: 855-67.
11. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
12. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-70.
13. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005; 308: 1318-21.
14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-310.
15. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009; 8: 709-23.
16. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9: 726-35.
17. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-49.
18. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006; 12: 2371s-5.
19. Williams DH, Wilkinson SE, Purton T, Lamont A, Flotow H, Murray EJ. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry 1998; 37: 9579-85.
20. Zhao A, Lee SH, Mojena M, et al. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK. J Antibiot (Tokyo) 1999; 52: 1086-94.
21. Moriguchi T, Kuroyanagi N, Yamaguchi K, et al. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 1996; 271: 13675-9.
22. Shirakabe K, Yamaguchi K, Shibuya H, et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun Nterminal kinase. J Biol Chem 1997; 272: 8141-4.
23. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGFbeta signal transduction. Science 1995; 270: 2008-11.
24. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007; 26: 3214-26.
25. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999; 398: 252-6.
26. Ninomiya-Tsuji J, Kajino T, Ono K, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 2003; 278: 18485-90.
27. Shao CL, Wu HX, Wang CY, et al. Potent antifouling resorcylic acid lactones from the gorgonian-derived fungus Cochliobolus lunatus. J Nat Prod 2011; 74: 629-33.
28. Ayers S, Graf TN, Adcock AF, et al. Resorcylic acid lactones with cytotoxic and NF-kappaB inhibitory activities and their structureactivity relationships. J Nat Prod 2011; 74: 1126-31.
29. Schirmer A, Kennedy J, Murli S, Reid R, Santi DV. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA 2006; 103: 4234-9.
30. Rastelli G, Rosenfeld R, Reid R, Santi DV. Molecular modeling and crystal structure of ERK2-hypothemycin complexes. J Struct Biol 2008; 164: 18-23.
31. Tatsuta K, Takano S, Sato T, Nakano S. The First Total Synthesis of a Macrocyclic Anti-protozoan, LL-Z1640-2. Chem. Lett. 2001: 172-73.
32. Selles P, Lett R. Convergent Stereospecific Synthesis of LLZ1640-2 (or C292), Hypothemycin and Related Macrolides. Part 2. Tetrahedron Lett. 2002; 43: 4627-31.
33. Dakas P-Y, Barluenga S, Totzke F, Zirrgiebel U, Winssinger N. Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. Angew Chem Int Ed 2007; 46: 6899-902.
34. Zhang W, Lu Y. Automation of fluorous solid-phase extraction for parallel synthesis. J Comb Chem 2006; 8: 890-6.
35. Dakas P-Y, Jogireddy R, Valot G, Barluenga S, Winssinger N. Divergent Syntheses of Resorcylic Acid Lactones: L-783277, LLZ1640-2, and Hypothemycin. Chem Eur J 2009; 15: 11490-7, S11490/1-S11490/44.
36. Choi HG, Son JB, Park DS, Ham YJ, Hah JM, Sim T. An efficient and enantioselective total synthesis of naturally occurring L-783277. Tetrahedron Lett. 2010; 51: 4942-6.
37. Evans DA, Black WC. Total synthesis of (+)-A83543A [(+)-lepicidin A]. J Am Chem Soc 1993; 115: 4497-513.
38. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-ring Lactonization. Bull Chem Soc Jpn 1979; 52: 1989-93.
39. Lin A, Willis AC, Banwell MG. An enantioselective synthesis of the resorcylic acid lactone L-783,277 via addition of an acetylide anion to a tethered Weinreb amide. Heterocycles 2011; 82: 313-8.
40. Hearn BR, Sundermann K, Cannoy J, Santi DV. Semisynthesis and cytotoxicity of hypothemycin analogues. ChemMedChem 2007; 2: 1598-600.
41. Liniger M, Neuhaus C, Hofmann T, et al. Kinase Inhibition by Deoxy Analogues of the Resorcylic Lactone L-783277. Med. Chem. Lett. 2011; 2: 22-7.
42. Napolitano C, Natoni A, Santocanale C, Evensen L, Lorens JB, Murphy PV. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorg. Med. Chem. Lett. 2011; 21: 1167-70.
43. Jogireddy R, Barluenga S, Winssinger N. Molecular Editing of inase-Targeting Resorcylic Acid Lactones (RAL): fluoroenone RAL. ChemMedChem 2010; 5: 670-3.
44. Barluenga S, Jogireddy R, Koripelly GK, Winssinger N. In vivo efficacy of natural product-inspired irreversible kinase inhibitors. Chembiochem 2010; 11: 1692-9.
45. Du H, Matsushima T, Spyvee M, et al. Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead. Bioorg Med Chem Lett 2009; 19: 6196-9.
46. Shen Y, Du H, Kotake M, et al. Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, II. Bioorg Med Chem Lett 2010; 20: 3047-9.
47. Shen Y, Boivin R, Yoneda N, et al. Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LLZ1640-2, III. Bioorg Med Chem Lett 2010; 20: 3155-7.
48. Drahl C, Cravatt BF, Sorensen EJ. Protein-reactive natural products. Angew Chem Int Ed Engl 2005; 44: 5788-809.
49. Smaill JB, Showalter HD, Zhou H, et al. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem 2001; 44: 429-40.
50. Tsou HR, Mamuya N, Johnson BD, et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001; 44: 2719-34.
51. Wissner A, Overbeek E, Reich MF, et al. Synthesis and structureactivity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003; 46: 49-63.
52. Wissner A, Hamann PR, Nilakantan R, et al. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles. Bioorg Med Chem Lett 2004; 14: 1411-6.
53. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5: 730-9.
54. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 2009; 12: 31-9.